CSL Ltd. — Investor Presentation 2023

Aug 14, 2023

For immediate release

15 August 2023

==> picture [596 x 198] intentionally omitted <==

RESULTS PRESENTATION FOR THE FULL YEAR ENDED 30 JUNE 2023

Melbourne, Australia – CSL (ASX:CSL; USOTC:CSLLY)

Please find attached the slides for the presentation on the full year results that will be given by the Chief Executive Officer and Chief Financial Officer shortly. The live briefing will be webcast and can be viewed at https://edge.media-server.com/mmc/p/e3vgbk4y/. Please note that this link will expire after the webcast concludes.

A recording of the webcast will be made available later in the day at: https://investors.csl.com/investors/financial-results-and-information

Authorised for lodgment by:

==> picture [97 x 45] intentionally omitted <==

Fiona Mead Company Secretary

For further information, please contact:

Investors:

Bernard Ronchi Director, Investor Relations CSL Limited P: +61 3 9389 3470 E: bernard.ronchi@csl.com.au

Stephen McKeon Director, Investor Relations CSL Limited P: 61 402 231 696

E: stephen.mckeon@csl.com.au

Media:

Jimmy Baker Communications CSL Limited P: +61 450 909 211

E: jimmy.baker@csl.com.au

==> picture [134 x 98] intentionally omitted <==

CSL Limited 2023 Full Year Results 15 August 2023

Paul McKenzie Joy Linton CEO & Managing Director CFO

IMPORTANT NOTICE AND DISCLAIMER

This presentation contains summary information about CSL Limited (ACN 051 588 348) and its related bodies corporate (together, CSL ) and CSL's activities as at the date of this presentation. It is information given in summary form only and does not purport to be complete. It should be read in conjunction with CSL's other periodic corporate reports and continuous disclosure announcements filed with the Australian Securities Exchange ( ASX ), available at www.asx.com.au This presentation is for information purposes only and is not a prospectus or product disclosure statement, financial product or investment advice or a recommendation to acquire CSL shares or other securities.

Legal Notice

No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. To the maximum extent permitted by law, none of CSL or its directors, employees or agents, nor any other person, accepts liability for any loss arising from the use of this presentation or its contents or otherwise arising in connection with it, including, without limitation, any liability from fault or negligence on the part of CSL or its directors, employees, contractors or agents.

This presentation contains forward-looking statements in relation to CSL, including statements regarding CSL's intent, belief, goals, objectives, initiatives, commitments or current expectations with respect to CSL's business and operations, market conditions, results of operations and financial conditions, products in research, risk management practices, climate change and other environmental and energy transition scenarios. Forward-looking statements can generally be identified by the use of words such as "forecast", "estimate", "plan", "will", "anticipate", "may", "believe", "should", "expect", “project,” "intend", "outlook", "target", "assume" and "guidance" and other similar expressions.

The forward-looking statements are based on CSL's good faith assumptions as to the financial, market, risk, regulatory and other relevant environments that will exist and affect CSL's business and operations in the future. CSL does not give any assurance that the assumptions will prove to be correct. The forward-looking statements involve known and unknown risks, uncertainties and assumptions and other important factors, many of which are beyond the control of CSL, that could cause the actual results, performances or achievements of CSL to be materially different to future results, performances or achievements expressed or implied by the statements . Factors that could cause actual results to differ materially include: the success of research and development activities, decisions by regulatory authorities regarding approval of our products as well as their decisions regarding label claims; competitive developments affecting our products; the ability to successfully market new and existing products; difficulties or delays in manufacturing; trade buying patterns and fluctuations in interest and currency exchange rates; legislation or regulations that affect product production, distribution, pricing, reimbursement, access or tax; acquisitions or divestitures; research collaborations; litigation or government investigations, advances in environmental protection processes, uncertainty and disruption caused by the COVID-19 pandemic and CSL’s ability to protect its patents and other intellectual property.

Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as at the date of the presentation. Except as required by applicable laws or regulations, CSL does not undertake any obligation to publicly update or revise any of the forward-looking statements or to advise of any change in assumptions on which any such statement is based.

TRADEMARKS

Except where otherwise noted, brand names designated by a ™or ® throughout this presentation are trademarks either owned by and/or licensed to CSL.

==> picture [74 x 56] intentionally omitted <==

2

01

CEO Overview Paul McKenzie CEO & Managing Director

==> picture [104 x 9] intentionally omitted <==

==> picture [79 x 60] intentionally omitted <==

3

Strong profit growth in FY23

CSL Behring

• Strong Ig growth

• Record plasma collections

• Successful launch of gene therapy HEMGENIX[®]

CSL Vifor

• Acquisition successfully closed Aug 22

• ~11 months contribution

• Integration well advanced

CSL Seqirus

• Strong growth in FLUCELVAX[®]

• Licence agreement for next-generation mRNA vaccine technology

R&D

• CSL 112 trial last patient in

• Garadacimab preparations for global regulatory submissions underway

REVENUE $13.3b +31%[1] NPATA[2] $2.6b[3 ] +20%[1]

NPAT $2.2b[3 ] +8%[1]

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail..

2. NPATA is defined as the statutory net profit after tax before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and unwind of the inventory fair value uplift 3. Attributable to the shareholders of CSL Limited

==> picture [74 x 56] intentionally omitted <==

4

==> picture [168 x 36] intentionally omitted <==

Revenue up 12%[1]

	Revenue	Change1			Major
Therapy	$m	%	Performance		Brands
			•	Strong growth across all geographies
Ig	4,675	21%	•	– Privigen® +29%, Hizentra® +12% Hizentra® pre filled syringe launch
			•	Global supply continues to recover strongly
Albumin	1,109	11%	• •	Strong growth in China as COVID restrictions ease Solid growth in US & EU as supply improves
			•	Strong performance by IDELVION® +13% due to:
Haemophilia	1,193	8%		– Increased HCP patient interactions – Continued uptake in Japan
			•	First patients dosed with HEMGENIX®
			•	Strong growth in KCENTRA® as social
Specialty	1,831	6%	•	mobility increases post-COVID Rebound in ZEMAIRA®/RESPREEZA® as
				supply returned
Other2	482	(15%)	•	Prior period inclusion of COVID vaccine sales
Total	9,290	12%

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail. 2. Includes HPV royalties, Hyperimmunes & sale of property

==> picture [74 x 56] intentionally omitted <==

5

==> picture [168 x 36] intentionally omitted <==

Operational Highlights

==> picture [54 x 54] intentionally omitted <==

Plasma Collections

• Strong increase in plasma collected +31%, now at record levels

• • ~14% reduction in CPL over the year[1]

• ~17% CPL reduction from the peak in March 2022

• Mexico border re-opened in Sep 22, centers recovering strongly

• • 12 new centers opened

• Continued advancement in digital technologies

• Further enhancements to the CSL Plasma donor app

• More than 3 million downloads

• Focused digital marketing campaigns

• Committed to roll-out of RIKA technology

==> picture [54 x 54] intentionally omitted <==

Manufacturing

• Broadmeadows and Marburg base fractionation facilities completed and opened

• Multiple yield initiatives underway

1. June-22 v June-23 US only

==> picture [256 x 476] intentionally omitted <==

==> picture [74 x 56] intentionally omitted <==

6

==> picture [165 x 36] intentionally omitted <==

Revenue up 9%[1]

Revenue $m Change1% Performance	Major Brands
Egg Based 148 (33%) Cell Culture 599 30% Adjuvanted Egg 893 7% • Continue to benefit from strength of differentiated product portfolio • 9% revenue growth in seasonal influenza vaccines against a backdrop of reduced rates of immunisation • Strong growth in FLUCELVAX® +30% • ~130 million doses distributed • US seasonal influenza vaccines >$1 billion for the second year running
Other / In License 211 25% TOTAL Product Sales 1,851 10% Pandemic 156 2% Other Income 24 4% • Includes sale of pre-pandemic Avian influenza vaccine
Total 2,031 9%

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

==> picture [74 x 56] intentionally omitted <==

7

==> picture [165 x 36] intentionally omitted <==

Operational Highlights

==> picture [54 x 54] intentionally omitted <==

Seasonal influenza products

• 6 months+ age indication for FLUCELVAX[®] now approved in the US, Argentina, Canada, Taiwan, Australia and New Zealand

• FLUAD included as a preferentially recommended seasonal vaccine option for adults aged 65+ years in the US

==> picture [54 x 54] intentionally omitted <==

Next-generation mRNA

• Licensing and Collaboration Agreement with Arcturus Therapeutics

• Access to late stage COVID-19 vaccine

• R&D development program beyond influenza

==> picture [54 x 54] intentionally omitted <==

Pandemic influenza

• Received BARDA orders for clinical assessment and stockpiling of H5 avian flu vaccine candidates

• Renewal/extension of Advance Purchase Agreements with Finland, Canada, Austria & Sweden

• Supplied AFLUNOV[®] pre-pandemic stockpile (H5N1) to Singapore

==> picture [54 x 54] intentionally omitted <==

Manufacturing

• Cell reassortment technology delivering higher yields

• Fill and finish fully operational at Holly Springs and Liverpool

• New cell-culture facility in Melbourne, expected to be operational in 2026

==> picture [74 x 56] intentionally omitted <==

8

==> picture [139 x 31] intentionally omitted <==

~11 months revenue contribution[1]

~14% revenue growth[2] Integration well advanced Cost synergies on track

	Revenue $m Major Brands Highlights
Iron	1,009 • Injectafer® approved in the US for the treatment of iron deficiency in adult patients with heart failure Jun 23 • Ferinject® launched in China Apr 23
Nephrology	Dialysis 771 • Strong Mircera®performance following agreement with large US kidney care provider • Successful launch of Kapruvia® in Germany and other EU countries • Long-term exclusive licensing agreement signed for Korsuva® in China

1. Acquired 9[th] August 2022 ~approximately 11 months contribution

2. Eleven months FY22 pre CSL ownership and unaudited versus eleven months FY23 at constant currency

==> picture [74 x 56] intentionally omitted <==

9

R&D Highlights – FY23

==> picture [43 x 41] intentionally omitted <==

Immunology

==> picture [43 x 41] intentionally omitted <==

Respiratory

==> picture [43 x 41] intentionally omitted <==

Transplant

• Garadacimab (Anti-FXIIa) HAE

• CSL787 (Neb Ig) Phase I study enrolment complete

• Phase III study data announced

• Preparations for global regulatory submissions underway

==> picture [43 x 41] intentionally omitted <==

Cardiovascular

• BERINERT® SC HAE JP PMDA launch

& Metabolic

• Anumigilimab (CSL324; G-CSFR antagonist) Phase Ib study complete

• CSL112 (ApoA ~~-~~ 1) Phase III study enrolment complete

• Clazakizumab (ESKD) Phase IIb/III first patient in

==> picture [43 x 41] intentionally omitted <==

Haematology

==> picture [42 x 42] intentionally omitted <==

• HEMGENIX ® (Etranacogene dezaparvovec)

Vaccines

• US Launch

• EU launch

  • aQIVc (cell antigen + MF59[®] ) Phase IIb study results available

• HOPE-B extension study 24-month data showed durable protection & sustained FIX activity

• KCENTRA® Trauma Phase III study first patient in • ARCT-154 COVID vaccine global submissions started

• CSL964 (AAT) treatment of GvHD ~~–~~ Phase III study last patient in

• Clazakizumab anti ~~-~~ IL ~~-~~ 6 mAB (AMR) ~~–~~ Phase III study 100 patients pass 1 year treatment mark

==> picture [78 x 18] intentionally omitted <==

• INJECTAFER® (ferric carboxymaltose) US label expansion for HF and ID-HF Phase III data available

• FERINJECT® (ferric carboxymaltose) ID China approval

• KORSUVA® /KAPRUVIA® (difelikefalin) multiple country approvals

• VELPHORO® (sucroferric oxyhydroxide) China approval

• SNF472 CUA Phase III study complete

• Sparsentan (IgAN) CMA EU submitted

• INS-3001 (AVS) Phase I study first patient in

Abbreviations: aQIVc – Adjuvanted Cell Culture Quadrivalent Influenza Vaccine; AVS – Aortic Valve Stenosis; CMA – Conditional Marketing Authorisation; CUA - Calcific Uremic Arteriolopathy; ESKD – End Stage Kidney Disease; EU – Europe; FIX – Factor IX; G-CSFR - Granulocyte Colony-Stimulating Factor Receptor; GvHD – Graft versus Host Disease; HAE – Hereditary Angioedema; HF – Heart Failure; ID – Iron Deficiency; IgAN - IgA Nephropathy; IPF - Idiopathic Pulmonary Fibrosis; JP – Japan; Neb Ig - Nebulised Ig; SC – Subcutaneous; SCD – Sickle Cell Disease; US – United States

==> picture [74 x 56] intentionally omitted <==

10

02

Financials Joy Linton CFO

==> picture [104 x 9] intentionally omitted <==

==> picture [79 x 60] intentionally omitted <==

11

NPATA[1]

NPATA1
$2,381m $2,610m $245m $2,855m2 FY22 NPATA FY23 NPATA @ CC 3 FX	FY22 Rep FY23 @ CC3
$2,381m $2,610m $245m $2,855m2 FY22 NPATA FY23 NPATA @ CC 3 FX
	NPATA $2,381m2 $2,855m2
	Acquired intangible assets amortisation ($115m) ($239m)
	One-off acquisition adjustments ($40m) ($346m)
	Tax $29m $84m4
	NPATA Attributable to NCI5 0 $139m
	NPAT $2,255m $2,493m
	NPAT Attributable to NCI5 0 ($52m)
	NPAT $2,255m2 $2,441m2

1. NPATA is defined as the statutory net profit after tax before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and unwind of the inventory fair value uplift 2. Attributable to the shareholders of CSL Limited.. FY23 includes ~11 months of CSL Vifor contribution

3. Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group

4.Tax attributable to amortisation of acquired intellectual property $35m (no impairment in FY23). Tax attributable to one-off acquisition adjustments (including unwind of the inventory fair value uplift) $49m 5. Non-Controlling Interest

==> picture [74 x 56] intentionally omitted <==

12

Ig franchise growing strongly

CSL Group

Financial Highlights

US$ Millions	FY22 Rep	FY23 Rep	FY23 at CC 1	Change % 1
Total Revenue	10,562	13,310	13,826	31%
Gross Profit3	5,734	7,250	7,587	32%
GP %3	54.3%	54.5%	54.9%
Sales & Marketing	961	1,454	1,515	58%
Operating Result3	4,773	5,796	6,072	27%
R&D3	1,043	1,232	1,269	22%
G&A3	648	907	825	27%
Finance (Net)	147	406	390	165%
NPATA2	2,381	2,610	2,855	20%
ETR %	18.9%	15.5%
ROIC %	18.1%	12.2%
Cashflow From Ops	2,629	2,601		(1%)4
NPATA EPS2 ($)	5.08	5.41	5.92	6%4
DPS ($)	2.22	2.36		6%4

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail

2. Attributable to the shareholders of CSL Limited.

3. Underlying results have been adjusted to exclude impairment and amortisation of acquired IP, business acquisition and transaction costs and unwind of the inventory fair value uplift

• 4.At reported currency

Includes ~11 months of CSL Vifor financials

S&M

CSL Behring and CSL Seqirus commercial activities relatively in line with prior year

R&D

11 months of CSL Vifor and progression of pipeline

G&A

11 months of CSL Vifor

Finance

Acquisition of CSL Vifor and higher interest rates

Tax

Lower ETR due to geographic profit mix and lower CSL Vifor ETR

Cashflow from Operations

Cash earnings growth offset by growth of plasma collections

==> picture [74 x 56] intentionally omitted <==

13

CSL Group FY23 by Segment

US$ Millions	CSL Behring	CSL Seqirus	Total	Change % at CC 1	Change % at CC 1	CSL Vifor 3	CSL Group	Change % at CC 1	Change % at CC 1
Sales	8,968	1,851	10,819	11%		1,957	12,776	31%
Other Revenue	322	180	502	23%		32	534	31%
Total Revenue	9,290	2,031	11,321	12%		1,989	13,310	31%
Gross Profit4	4,575	1,264	5,839	7%		1,411	7,250	32%
GP %2,4	50.4%	59.7%	52.0%			71.3%	54.9%
Sales & Marketing	782	182	964	4%		490	1,454	58%
Operating Result	3,793	1,082	4,875	8%		921	5,796	27%
Operating Segment %2,4	41.9%	50.8%	43.5%			46.1%	43.9%

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

2. Percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail. 3. Acquired 9[th] August 2022 ~approximately 11 months contribution

4.Underlying results have been adjusted to exclude impairment and amortisation of acquired IP, business acquisition and transaction costs and unwind of the inventory fair value uplift

==> picture [74 x 56] intentionally omitted <==

14

CSL Behring Gross Margin

CPL Reduction

New Products[2] ASP Mix Shift Ig Yield Improvements[3]

Scale & Efficiency Measures

Path to margin recovery different to COVID driven margin decline

Anticipate margin to return to pre-COVID level within 3 – 5 years

FX impacts margin given ~50% of sales outside US

Continued balance of marginal litre products

1. Illustrative only

2. CSL112 not included

3. Horizon 1 yield improvements only. See slide Yield Maximisation slide for further detail

==> picture [74 x 56] intentionally omitted <==

15

Operational Efficiency

==> picture [406 x 306] intentionally omitted <==

----- Start of picture text -----

$M Revenue % of Revenue
14,000 8%
12,000
6%
10,000
8,000
4%
6,000
4,000
2%
2,000
0 0%
FY20 FY21 FY22 FY23
Total Revenue G&A % rev1
----- End of picture text -----

Enterprise wide enabling functions successfully embedded

• Centralised services provided to the businesses

• I&T, HR, Finance, Comms, Legal, Procurement

• Benefit from scale, automation and standardisation

• Enhances internal controls

Further leverage opportunities

==> picture [74 x 56] intentionally omitted <==

16

1. Excludes FX Gains/Losses

Inventory Active management

==> picture [573 x 288] intentionally omitted <==

----- Start of picture text -----

$m Inventory % of revenue
6,000 100%
5,000
80%
4,000
60%
3,000
40%
2,000
20%
1,000
0 0%
2017 2018 2019 2020 2021 2022 2023
Finished Goods Work in Progress Raw Materials Inventory % Revenue
----- End of picture text -----

==> picture [257 x 228] intentionally omitted <==

----- Start of picture text -----

Key Insights
----- End of picture text -----

Inventory as a percentage of revenue steady despite dynamic environment

Higher inventory driven by increased plasma volume and cost Includes CSL Vifor for the first time

==> picture [74 x 56] intentionally omitted <==

17

Capex Management[1]

==> picture [613 x 329] intentionally omitted <==

----- Start of picture text -----

Capex US$m % of Revenue
1,400 14%
~30% 13%
1,200
12%
1,000 11%
10%
800
9%
600
8%
7%
400
6%
200
5%
- 4%
Maint Growth % of Rev
----- End of picture text -----

1. Capital Expenditure for Property, Plant & Equipment - net of disposals

~70% in growth capex v maintenance capex over the last 4 years to support future demand FY24 expected to be ~$800m

~30% down on FY23

==> picture [74 x 56] intentionally omitted <==

18

Foreign Currency Impact

NPATA – FX impact by type

==> picture [411 x 193] intentionally omitted <==

----- Start of picture text -----

($245m)
$2,855m
$64m
$49m
$47m
$31m
$23m
$31m $2,610m
FY23 @ CC USD/CNY USD/GBP USD/EUR USD/JPY USD/AUD Other FY23
----- End of picture text -----

NPATA – FX impact by type

==> picture [328 x 196] intentionally omitted <==

----- Start of picture text -----

($245m)
$2,855m
$121m
$116m
$2,610m
$8m
FY23 @ CC Transaction FX Unrealised Translation FX FY23
/ Realised FX
----- End of picture text -----

Currency Average Rates

Change

	FY23	FY22	%
USD/EUR	0.96	0.88	8.5%
USD/GBP	0.83	0.75	11.2%
USD/AUD	1.49	1.37	8.3%
USD/CNY	6.95	6.44	7.9%
USD/CHF	0.94	0.93	1.5%
USD/JPY	137.21	116.30	18.0%

$245m NPATA FX headwind

• Volatility in global currency markets

• Largely driven by a strong USD

Transaction FX impact contingent on timing of sales & relevant exchange rates

==> picture [74 x 56] intentionally omitted <==

19

03

CEO Overview Paul McKenzie CEO & Managing Director

==> picture [104 x 9] intentionally omitted <==

==> picture [35 x 19] intentionally omitted <==

20

Ig Yield Maximisation Strategy[1]

==> picture [48 x 241] intentionally omitted <==

----- Start of picture text -----

Ig Yield
Growth
25%
20%
15%
10%
----- End of picture text -----

==> picture [599 x 402] intentionally omitted <==

----- Start of picture text -----

Growth
25%
20% Horizon 2
15%
10%
5% Horizon 1
Baseline
Pre Covid FY23 FY30
----- End of picture text -----

1. Illustrative only

Subject to the success and timing of research and development activities and the decisions of regulatory authorities

==> picture [320 x 197] intentionally omitted <==

----- Start of picture text -----

•
FY23 recovery ~70 – ~75% of IG (yield
~4.52g)
•
US average donor has 6 – 6.5g of IG
•
Horizon 1 FY24 – FY28 – recovery to
grow +5%
----- End of picture text -----

• Horizon 2 FY29 – FY33 – recovery to grow +10% Yield Improvements

• Over 10 year period, expect ~90% IG

• Horizon 1 recovery

• • Process changes within regulatory filing

• • Data analytics and plasma allocation • [NEED TO LIST SOME OF THE • Operational excellence ACTIVITIES IN A BIT MORE DETAIL OR LEAVE FOR VERBAL OVERLAY?]

• Horizon 2 • Proprietary process improvements with some manufacturing re-tooling

• • Will require regulatory approval

• • Targeted at litres producing Ig & Albumin only

• Pilot work underway

==> picture [74 x 56] intentionally omitted <==

21

FY24 Outlook[1] Strong mid-term outlook Promising cluster of R&D programs nearing completion

• CSL Behring CSL Vifor • • Strong Ig growth following Investing in Iron record FY23 plasma to win in an collections evolving market

CSL Seqirus

• Continued growth from Influenza vaccine differentiation

• •

• Gene therapy HEMGENIX[®] Organising for US & EU commercialisation commercial and

• • operational Initiatives underway in efficiency

• Progressing global registrations for nextgeneration mRNA COVID vaccine

• Initiatives underway in support of mid-term margin recovery

==> picture [223 x 320] intentionally omitted <==

----- Start of picture text -----

Revenue Growth
----- End of picture text -----

~ 9 – 11% @CC[2 ]

Patient Blood Management strategic initiative

NPATA Growth

One CSL R&D, including combining nephrology and transplant therapeutic area

• 1 For forward looking statements, refer to Legal Notice on page 2

  • ~ 13 – 17% @CC[2,3 ] to

  • ~$2.9 – $3.0b @CC[2,4]

• 2 Constant Currency (CC) removes the impact of exchange rate movements to facilitate comparability. See end note for further detail

• 3 % growth rates exclude the one-off gain from the sale of property in FY23 (NPATA $44m)

• 4 NPATA to NPAT adjustments are estimated to be:

• Amortisation of acquired intellectual property. FY24 estimate $300m (pre-tax), $260m (post tax)

• CSL Vifor integration costs and the unwind of inventory fair value uplift. FY24 estimate $85m (pre-tax), $70m (post-tax)

• FY24 FX impact expected to be immaterial if current rates remain unchanged for the remainder of the financial year

==> picture [74 x 56] intentionally omitted <==

22

==> picture [101 x 89] intentionally omitted <==

CSL Contacts

Mark Dehring VP Investor Relations  +61 3 9389 3407 mark.dehring@csl.com.au

Bernard Ronchi Investor Relations  +61 3 9389 3470 bernard.ronchi@csl.com.au

Stephen McKeon Investor Relations  +61 3 9389 6798 stephen.mckeon@csl.com.au

==> picture [256 x 256] intentionally omitted <==

Notes

Summary NPAT attributable to members
of parent entity
Reportednetprofit after tax	$2,194m
Currency effect	$247m
Constant currency net profit after tax*	$2,441m

(#) Constant currency removes the impact of exchange rate movements to facilitate comparability of operational performance for the Group. This is done in three parts: a) by converting the current year net profit of entities in the group that have reporting currencies other than US Dollars, at the rates that were applicable to the prior comparable period (translation currency effect); b) by restating material transactions booked by the group that are impacted by exchange rate movements at the rate that would have applied to the transaction if it had occurred in the prior comparable period (transaction currency effect); and c) by adjusting for current year foreign currency gains and losses. The sum of translation currency effect, transaction currency effect and foreign currency gains and losses is the amount by which reported net profit is adjusted to calculate the operational result.

Average exchange rates for major currencies for half year ended 30 June 2023/30 June 2022 include: USD/EUR (0.96/0.88), USD/AUD (1.49/1.37), USD/CHF (0.94/0.93), USD/CNY (6.95/6.44) and USD/GBP (0.83/0.75).

	Summary NPATA1 attributable to
	members of the parent entity	US$m
	Reported net profit after tax	2,194
	Amortisation of acquired intellectual property	181
	Unwind of inventory fair value uplift	122
	Acquisition and integration costs	184
	Income tax credit on above adjustments	(71)
	NPATA1attributable to members of the parent entity	2,610
	Currency effect attributable to members of the parent entity	245
	Constant Currency# NPATA1attributable to members of the parent entity	2,855

Summary Revenue
Reported revenue $13,310m
Currency effect $ 516m
Constant currency revenue* $13,826m
*Constant currency net profit after tax and
constant currency sales have not been audited or
reviewed in accordance with Australian Auditing
Standards.

General Disclaimer Non-IFRS

There are references to IFRS (International Financial Reporting Standards) and non-IFRS financial information in this document. Non-IFRS financial measures are financial measures other than those defined or specified under any relevant accounting standard and may not be directly comparable with other companies’ information. Non-IFRS financial measures are used to enhance the comparability of information between reporting periods, and enable further insight and a different perspective into the financial performance. Non-IFRS financial information should be considered in addition to, and is not intended to be a substitute for, IFRS financial information and measures. Non-IFRS financial measures are not subject to audit or review.

==> picture [74 x 56] intentionally omitted <==

1. NPATA is defined as the statutory net profit after tax before impairment and amortisation of acquired intellectual property, business acquisition and integration costs and unwind of the inventory fair value uplift

24

==> picture [84 x 95] intentionally omitted <==

Appendix

==> picture [74 x 56] intentionally omitted <==

25

Appendix A CSL Behring – Key Products

CSL BEHRING	Therapy Group	Sales $m	Change1%
Privigen	IVIG	2,832	29%
Hizentra	SCIG	1,644	12%
Albumin	Albumin	1,109	11%
Idelvion	Haemophilia	703	13%
Kcentra	Specialty	666	10%
Haegarda	Specialty	436	1%
Berinert	Specialty	259	1%
Haemocomplettan	Specialty	217	4%
Intragam	IVIG	184	(15%)
Humate	Haemophilia	170	2%

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail

FY23 Revenue By Therapy Group $m

==> picture [280 x 244] intentionally omitted <==

----- Start of picture text -----

5%,
9% Other,
Other $482
Specialty
$867 33%
10%, IVIG
Peri-Operative $3,028
Bleeding,
$964
4%,
Plasma,
$379
9%
Recombinants
$814
18%,
12%,
SCIG,
Albumin,
$1,647
$1,109
----- End of picture text -----

==> picture [74 x 56] intentionally omitted <==

26

Appendix B CSL Vifor & CSL Seqirus – Key Products

CSL SEQIRUS	Therapy Group	Sales $m	Change1%
Fluad	Adjuvanted	893	7%
Flucelvax	Cell culture	599	30%
Afluria	Egg-based	134	(32%)

CSL VIFOR	Therapy Group	Sales $m
Ferinject / Injectafer	Iron	759
Mircera	Dialysis	533
Velphoro	Dialysis	175
Venofer	Iron	172
Veltassa	Non Dialysis	112
Maltofer	Iron	75

1. Growth percentages shown at constant currency to remove the impact of exchange rate movements, facilitating comparability of operational performance. See end note for further detail.

==> picture [407 x 493] intentionally omitted <==

----- Start of picture text -----

FY23 Revenue By Therapy Group $m
1%, Other Income,
$24
8%, Pandemic, $156
7%, Egg Based, $148
10%, Other / In License,
$211
30%,
Cell Culture,
$599
44% ,
Adjuvanted,
$893
3%, Other, $73
7%, Non Dialysis,
$136
51%,
Iron,
$1,009
39%,
Dialysis,
$771
----- End of picture text -----

27